Biologics Drug Discovery.
Eliminate variability & optimize your lead candidates.
Monoclonal antibodies (mAbs) are characterized by their vast diversity in both structure and activity. As such, researchers may evaluate hundreds of mAbs while identifying their best binders. But this selection process can take months as conventional biologics discovery techniques do not include tools that can truly assess mAb biophysical diversity that directly affects specificity and affinity. With REmAb®’s next generation protein sequencing platform, mAb leads can be analyzed down to the amino acid level, including PTMs for targeted and controlled development in parallel.
Polyclonal antibodies (pAbs) are well used in drug discovery research because they recognize and bind many different epitopes of a single antigen. However, because the identity and sequence of each antibody in the mixture is unknown, polyclonal mixtures are difficult to work with. Current biologics discovery methods are indirect, expensive and time consuming. The advent of Polyclonal Antibody sequencing allows researchers to directly access high-affinity antibodies from the native immune response, derive their amino acid sequences and express a set of mAbs that perform as well or better than the original polyclonal mixture. Polyclonal antibody sequencing is the most direct method for therapeutic antibody discovery.
Biologics drug discovery services.
Rapid Novor’s next generation protein sequencing services empower scientists to discover potent biologics they can characterize faster by giving them direct access to the functional protein’s amino acid sequence and PTMs. By leveraging their extensive proteomics expertise, Rapid Novor also offers sequence verification throughout the biologics pipeline for peace-of-mind and utmost quality.
Mine the immune response
Exploit the biologics potential of the circulating polyclonal response. Access a wide array of biologically relevant CDRs for antibody engineering. Or extract exact sequences from the diverse antibody repertoire for recombinant expression.
Explore REpAb + Expression
Evaluate mAb leads faster
Already have an established hybridoma pipeline? Examine fusion products and derive the sequence of important candidates, or extract the CDR sequences to add to your framework or platform for future engineering.
Explore REmAb
Secure research efforts
A biologic’s amino acid sequence is often integral to its IP. Thanks to Rapid Novor’s next generation protein sequencing, scientists from the top 18 pharma have safeguarded their discoveries by directly accessing the protein sequence of their mAb drugs.
Explore MATCHmAb
Quality Control and Troubleshooting
Routinely confirm that your produced antibody matches the expected or engineered sequence. Save time troubleshooting PTM vs. mutations and substitutions throughout your pipeline.
Explore MATCHmAb
Regulatory Approval and ADA
Anti-drug antibody assays are vital to establish clinical safety and efficacy of biologics. REpAb® polyclonal antibody sequencing can capture reliable control reagents that faithfully recapitulate the ADA response.
Explore REpAb
Application Publications.
Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing
Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.
Ushering in the Future of Immunotherapy with Protein Sequencing
Dating back to ancient Egypt, immunotherapy has a rich history of harnessing the power of the immune response to treat diseases. Today, immunotherapy is routinely used to fight cancer and treat viral diseases.
De Novo Protein Sequencing
Abstract In this on-demand webinar, we briefly cover the fundamentals of protein sequencing, how researchers have benefited from implementing protein [...]
Monoclonal Vs. Polyclonal Antibody Drugs
The transition from polyclonal antibody drugs to a more targeted monoclonal approach was made possible through a series of scientific and technological advancements; the most notable of which is the hybridoma technique developed by Köhler and Milstein, which allowed the generation of pure antibodies at scale.
“We’re focused on coupling cytokines with a highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to graft them into our platform and test in vitro and in vivo.”
Talk to Our Scientists.
We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics